Richard Klausner - 15 Aug 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Charles Newton, as Attorney-in-fact
Issuer symbol
LYEL
Transactions as of
15 Aug 2023
Net transactions value
-$132,286
Form type
4
Filing time
17 Aug 2023, 16:23:14 UTC
Previous filing
20 Jun 2023
Next filing
08 Sep 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Sale $132,286 -58,020 -5.9% $2.28 930,880 15 Aug 2023 Grantor F1, F2
holding LYEL Common Stock 2,967,834 15 Aug 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.275 to $2.285, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 Consists of 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust, 245,515 shares held by The Isaac Klausner Delaware Trust, and 245,515 shares held by The Olivia Klausner Delaware Trust. The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein. Raymond James Trust Services of Delaware is the trustee of each of the trusts.